TrialInternational journal of rheumatic diseases2016

A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.

Rajendrakumar H Jani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.